Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclobutrifluram is a novel small molecule pesticide developed primarily as a succinate dehydrogenase (SDH) inhibitor, targeting the mitochondrial electron transport chain complex II (succinate:ubiquinone oxidoreductase)[3][1][5]. It functions as a selective SDH inhibitor (IRAC Group N-3), disrupting ATP production in the mitochondria of nematodes and fungi, leading to impaired survival, growth, and reproduction of these pests[1][3][5]. Cyclobutrifluram is used as both a seed and soil treatment, protecting plant roots by controlling major plant-parasitic nematodes (e.g., Meloidogyne, Pratylenchus, Heterodera, Nacobbus species) and certain soil-borne fungal diseases (e.g., Fusarium, Macrophomina phaseolina, Alternaria dauci, Cercospora carotae)[1][7]. Developed by Syngenta, cyclobutrifluram is notable for its effectiveness against nematodes, including Bursaphelenchus xylophilus (pine wood nematode), and for reducing the incidence of diseases such as pine wilt disease[3]. In laboratory studies with Caenorhabditis elegans, cyclobutrifluram significantly decreases germ cell proliferation and fertility, indicating its mechanism of action involves inhibition of mitochondrial complex II, which is critical for cellular respiration[5]. Cyclobutrifluram is formulated as a suspension concentrate (SC) for agricultural use, typically applied to soil or seeds, with products like TREFINTI (turf nematicide, 450 g/L cyclobutrifluram) manufactured overseas[1]. It is stable under normal storage conditions for at least one year[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclobutrifluram.